0.75
price down icon3.49%   -0.0271
 
loading
Precedente Chiudi:
$0.7771
Aprire:
$0.81
Volume 24 ore:
416.65K
Relative Volume:
0.86
Capitalizzazione di mercato:
$31.47M
Reddito:
$2.93M
Utile/perdita netta:
$-25.30M
Rapporto P/E:
-1.3985
EPS:
-0.5363
Flusso di cassa netto:
$-33.59M
1 W Prestazione:
-1.19%
1M Prestazione:
+13.50%
6M Prestazione:
-11.25%
1 anno Prestazione:
-35.90%
Intervallo 1D:
Value
$0.75
$0.8254
Intervallo di 1 settimana:
Value
$0.7302
$0.8399
Portata 52W:
Value
$0.565
$1.31

Scynexis Inc Stock (SCYX) Company Profile

Name
Nome
Scynexis Inc
Name
Telefono
201-884-5485
Name
Indirizzo
1 EVERTRUST PLAZA, JERSEY CITY, NJ
Name
Dipendente
29
Name
Cinguettio
@scynexis
Name
Prossima data di guadagno
2024-11-11
Name
Ultimi documenti SEC
Name
SCYX's Discussions on Twitter

Compare SCYX vs TAK, ZTS, HLN, TEVA, UTHR

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - Specialty & Generic icon
SCYX
Scynexis Inc
0.75 32.61M 2.93M -25.30M -33.59M -0.5363
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
18.46 58.03B 29.85B 776.90M 4.35B 0.2408
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
126.65 55.37B 9.40B 2.65B 2.24B 5.935
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
11.20 49.70B 14.26B 1.98B 2.47B 0.4327
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
33.98 39.50B 17.41B 1.43B 1.00B 1.2182
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
473.66 20.50B 3.13B 1.27B 1.12B 26.39

Scynexis Inc Stock (SCYX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2021-01-22 Iniziato Guggenheim Buy
2021-01-06 Iniziato Cantor Fitzgerald Overweight
2018-07-11 Aggiornamento Needham Hold → Buy
2018-06-27 Iniziato Maxim Group Buy
2017-10-24 Iniziato Guggenheim Buy
2017-07-10 Iniziato ROTH Capital Buy
2017-05-09 Downgrade Needham Buy → Hold
2017-03-03 Reiterato RBC Capital Mkts Outperform
2016-10-20 Iniziato H.C. Wainwright Buy
2016-10-07 Aggiornamento WBB Securities Buy → Strong Buy
2016-10-03 Ripresa Brean Capital Buy
2016-08-17 Iniziato Guggenheim Buy
2016-08-09 Reiterato Needham Buy
2016-08-09 Aggiornamento WBB Securities Speculative Buy → Buy
2016-03-28 Iniziato Brean Capital Buy
2015-12-29 Iniziato WBB Securities Speculative Buy
2015-11-16 Reiterato RBC Capital Mkts Outperform
2015-06-10 Iniziato Needham Buy
2014-05-29 Iniziato Canaccord Genuity Buy
2014-05-29 Iniziato RBC Capital Mkts Outperform
Mostra tutto

Scynexis Inc Borsa (SCYX) Ultime notizie

pulisher
Feb 12, 2026

Market Moves: Is SCYNEXIS Inc backed by strong institutional buyingQuarterly Portfolio Report & AI Forecast Swing Trade Picks - baoquankhu1.vn

Feb 12, 2026
pulisher
Feb 09, 2026

Invasive Fungal Infections Market to Witness Upsurge in Growth at a CAGR of 11.4% (in the US) During the Forecast Period (2025-2034) | DelveInsight - The AI Journal

Feb 09, 2026
pulisher
Feb 07, 2026

FOMO Trade: Does SCYNEXIS Inc have pricing powerJuly 2025 Levels & Community Driven Trade Alerts - baoquankhu1.vn

Feb 07, 2026
pulisher
Feb 06, 2026

Swing Trade: Is SCYNEXIS Inc backed by strong institutional buyingMarket Performance Summary & Weekly Consistent Profit Watchlists - baoquankhu1.vn

Feb 06, 2026
pulisher
Jan 29, 2026

SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting - marketscreener.com

Jan 29, 2026
pulisher
Jan 28, 2026

Scynexis (SCYX) to Present Data on Advanced Antifungal Drug at K - GuruFocus

Jan 28, 2026
pulisher
Jan 28, 2026

SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI) - The Manila Times

Jan 28, 2026
pulisher
Jan 28, 2026

New antifungal SCY-247 shows potent activity against deadly drug-resistant fungi - stocktitan.net

Jan 28, 2026
pulisher
Jan 24, 2026

Companies Like SCYNEXIS (NASDAQ:SCYX) Could Be Quite Risky - Sahm

Jan 24, 2026
pulisher
Jan 23, 2026

Aug Macro: Can SCYNEXIS Inc expand into new marketsQuarterly Earnings Summary & Safe Entry Trade Reports - baoquankhu1.vn

Jan 23, 2026
pulisher
Jan 22, 2026

JERSEY CITYFDA grants fast track and QIDP designations to SCYNEXIS drug - Investing.com Nigeria

Jan 22, 2026
pulisher
Jan 21, 2026

Scynexis (SCYX) Gains FDA Designations for Antifungal Therapy SC - GuruFocus

Jan 21, 2026
pulisher
Jan 21, 2026

Scynexis receives FDA qualified infectious disease product and fast track designations for SCY-247 - marketscreener.com

Jan 21, 2026
pulisher
Jan 21, 2026

SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247 - The Manila Times

Jan 21, 2026
pulisher
Jan 21, 2026

FDA fast-tracks new antifungal aimed at deadly Candida auris infections - Stock Titan

Jan 21, 2026
pulisher
Jan 18, 2026

Breakout Move: Is SCYNEXIS Inc benefiting from innovation trendsMarket Sentiment Review & Risk Controlled Stock Pick Alerts - baoquankhu1.vn

Jan 18, 2026
pulisher
Jan 17, 2026

Aug Volume: Is SCYNEXIS Inc stock trending bullishWeekly Trade Analysis & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn

Jan 17, 2026
pulisher
Jan 14, 2026

FEDERATED HERMES, INC. Acquires Additional Shares in SCYNEXIS Inc. - GuruFocus

Jan 14, 2026
pulisher
Jan 14, 2026

Retail Trends: Can SCYNEXIS Inc expand into new marketsWeekly Gains Report & Short-Term Swing Trade Alerts - baoquankhu1.vn

Jan 14, 2026
pulisher
Jan 14, 2026

RSI Check: Is SCYNEXIS Inc benefiting from innovation trendsWeekly Trend Report & AI Based Buy/Sell Signal Reports - baoquankhu1.vn

Jan 14, 2026
pulisher
Jan 13, 2026

Jobs Data: Will SCYNEXIS Inc stock continue dividend increasesJuly 2025 Levels & Community Driven Trade Alerts - Bộ Nội Vụ

Jan 13, 2026
pulisher
Jan 11, 2026

Published on: 2026-01-11 17:42:44 - Улправда

Jan 11, 2026
pulisher
Jan 10, 2026

SCYNEXIS halts phase 3 MARIO trial, raising new questions for ibrexafungerp’s growth path - MSN

Jan 10, 2026
pulisher
Jan 10, 2026

Why SCYNEXIS Inc. (135A) stock is listed among top recommendationsJobs Report & Low Risk Investment Opportunities - ulpravda.ru

Jan 10, 2026
pulisher
Jan 08, 2026

Why hedge funds are buying SCYNEXIS Inc. stockWeekly Trade Summary & AI Driven Price Predictions - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

Gains Report: Does SCYNEXIS Inc stock trade at a discount to peersWeekly Trade Recap & Expert Curated Trade Ideas - Bộ Nội Vụ

Jan 08, 2026
pulisher
Jan 08, 2026

How SCYNEXIS Inc. stock compares to industry benchmarksOptions Play & Daily Stock Momentum Reports - Улправда

Jan 08, 2026
pulisher
Jan 07, 2026

Why SCYNEXIS Inc. stock is trending among retail tradersResistance Breakout Alerts & Free Rapid Return Acceleration - bollywoodhelpline.com

Jan 07, 2026
pulisher
Dec 27, 2025

Portfolio Update: How SCYNEXIS Inc stock compares to industry benchmarksJuly 2025 Highlights & Free Safe Capital Growth Stock Tips - moha.gov.vn

Dec 27, 2025
pulisher
Dec 26, 2025

SCYNEXIS granted Nasdaq extension to regain bid price compliance - MSN

Dec 26, 2025
pulisher
Dec 25, 2025

What analysts say about SCYNEXIS Inc 135A stockFundamental Strength Indicators & Build Wealth With Expert Timing Advice - earlytimes.in

Dec 25, 2025
pulisher
Dec 22, 2025

Scynexis receives 180-day extension from Nasdaq to meet listing requirements - Investing.com

Dec 22, 2025
pulisher
Dec 22, 2025

Scynexis granted 180-day extension by Nasdaq to regain compliance with minimum bid price requirement - marketscreener.com

Dec 22, 2025
pulisher
Dec 22, 2025

SCYNEXIS, Inc. Receives 180-Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price Requirement - Quiver Quantitative

Dec 22, 2025
pulisher
Dec 22, 2025

SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement - The Manila Times

Dec 22, 2025
pulisher
Dec 21, 2025

Earnings Report: Why SCYNEXIS Inc. stock is trending among retail tradersAnalyst Downgrade & Long Hold Capital Preservation Plans - Улправда

Dec 21, 2025
pulisher
Dec 21, 2025

SCYNEXIS Earnings Notes - Trefis

Dec 21, 2025
pulisher
Dec 20, 2025

Is SCYNEXIS Inc. stock trading at a premium valuationEarnings Risk Summary & Reliable Volume Spike Alerts - Улправда

Dec 20, 2025
pulisher
Dec 20, 2025

Shorts Report: How SCYNEXIS Inc. (135A) stock compares with tech leadersEarnings Summary Report & Safe Entry Momentum Stock Tips - moha.gov.vn

Dec 20, 2025
pulisher
Dec 19, 2025

SCYNEXIS Halts Phase 3 MARIO Trial, Raising New Questions for Ibrexafungerp’s Growth Path - TipRanks

Dec 19, 2025
pulisher
Dec 19, 2025

Will SCYNEXIS Inc. stock deliver better than expected guidance2025 Key Lessons & Advanced Swing Trade Entry Plans - DonanımHaber

Dec 19, 2025
pulisher
Dec 19, 2025

Can SCYNEXIS Inc. stock continue upward trendEarnings Summary Report & Long-Term Growth Stock Strategies - Улправда

Dec 19, 2025
pulisher
Dec 19, 2025

How SCYNEXIS Inc. (135A) stock compares with tech leadersJuly 2025 Momentum & Verified Stock Trade Ideas - Bölüm Sonu Canavarı

Dec 19, 2025
pulisher
Dec 19, 2025

Why SCYNEXIS Inc. stock is a must watch in 2025Market Trend Review & Fast Momentum Stock Entry Tips - Улправда

Dec 19, 2025
pulisher
Dec 18, 2025

Nasdaq Moves: Why SCYNEXIS Inc. stock is a must watch in 2025Weekly Stock Recap & AI Powered Market Trend Analysis - Улправда

Dec 18, 2025
pulisher
Dec 18, 2025

Is SCYNEXIS Inc. stock a contrarian buy2025 Trading Volume Trends & AI Powered Buy and Sell Recommendations - ulpravda.ru

Dec 18, 2025
pulisher
Dec 18, 2025

What insider purchases suggest about SCYNEXIS Inc. (135A) stockJuly 2025 Macro Moves & AI Enhanced Trading Alerts - ulpravda.ru

Dec 18, 2025
pulisher
Dec 11, 2025

Revenue per share of SCYNEXIS, Inc. – BER:135A - TradingView — Track All Markets

Dec 11, 2025
pulisher
Dec 08, 2025

SCYNEXIS (NASDAQ:SCYX) versus NewAmsterdam Pharma (NASDAQ:NAMS) Head to Head Analysis - Defense World

Dec 08, 2025

Scynexis Inc Azioni (SCYX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
drug_manufacturers_specialty_generic RDY
$14.14
price down icon 1.19%
$124.12
price up icon 0.83%
$25.13
price up icon 1.37%
drug_manufacturers_specialty_generic RGC
$31.22
price up icon 7.58%
$15.77
price down icon 0.13%
$473.66
price down icon 0.52%
Capitalizzazione:     |  Volume (24 ore):